Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 191

1.

Importance of high-quality ANA testing for SLE classification. Response to: 'Role of ANA testing in the classification of patients with systemic lupus erythematosus' by Pisetsky et al.

Aringer M, Costenbader KH, Dörner T, Johnson SR.

Ann Rheum Dis. 2019 Oct 11. pii: annrheumdis-2019-216337. doi: 10.1136/annrheumdis-2019-216337. [Epub ahead of print] No abstract available.

PMID:
31604707
2.

Difference between SLE classification and diagnosis and importance of attribution. Response to: 'Do the 2019 EULAR/ACR SLE classification criteria close the door on certain groups of SLE patients?' by Chi et al.

Aringer M, Costenbader KH, Dörner T, Johnson SR.

Ann Rheum Dis. 2019 Oct 4. pii: annrheumdis-2019-216338. doi: 10.1136/annrheumdis-2019-216338. [Epub ahead of print] No abstract available.

PMID:
31585929
3.

[Future of rheumatologists: what are the perspectives? : Survey of resident physicians in rheumatology in middle Germany].

Pfeil A, Baerwald CGO, Sieburg M, Boche K, Kupka TA, Linde T, Heldmann F, Unger L, Oelzner P, Aringer M, Keyßer G.

Z Rheumatol. 2019 Sep 30. doi: 10.1007/s00393-019-00713-1. [Epub ahead of print] German.

PMID:
31570975
4.

Treat to Target in Systemic Lupus Erythematosus.

Aringer M, Leuchten N, Schneider M.

Rheum Dis Clin North Am. 2019 Nov;45(4):537-548. doi: 10.1016/j.rdc.2019.07.004. Epub 2019 Aug 22. Review.

PMID:
31564295
5.

Associations among classification criteria items within systemic lupus erythematosus.

Touma Z, Cervera R, Brinks R, Lorenzoni V, Tani C, Hoyer BF, Costenbader KH, Sebastiani GD, Navarra SV, Bonfa E, Ramsey-Goldman R, Tedeschi SK, Dörner T, Johnson SR, Aringer M, Mosca M; ACR/EULAR group, New SLE classification criteria for clinical research are being developed, sponsored by EULAR, ACR.

Arthritis Care Res (Hoboken). 2019 Sep 27. doi: 10.1002/acr.24078. [Epub ahead of print]

PMID:
31560454
6.

Response to: 'New 2019 SLE EULAR/ACR classification criteria are valuable for distinguishing patients with SLE from patients with pSS' by Assan et al.

Aringer M, Costenbader K, Dörner T, Johnson SR.

Ann Rheum Dis. 2019 Sep 18. pii: annrheumdis-2019-216250. doi: 10.1136/annrheumdis-2019-216250. [Epub ahead of print] No abstract available.

PMID:
31533932
7.

Multiparametric Analysis of Connective Tissue Disease Specific Autoantibodies Using a Spot Immunoassay.

Röber N, Rejzek M, Aringer M, Rudolph S, Unger L, Lüthke K, Gräßler A, Conrad K.

Clin Lab. 2019 Sep 1;65(9). doi: 10.7754/Clin.Lab.2019.190218.

PMID:
31532087
8.

2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus.

Aringer M, Costenbader K, Daikh D, Brinks R, Mosca M, Ramsey-Goldman R, Smolen JS, Wofsy D, Boumpas DT, Kamen DL, Jayne D, Cervera R, Costedoat-Chalumeau N, Diamond B, Gladman DD, Hahn B, Hiepe F, Jacobsen S, Khanna D, Lerstrøm K, Massarotti E, McCune J, Ruiz-Irastorza G, Sanchez-Guerrero J, Schneider M, Urowitz M, Bertsias G, Hoyer BF, Leuchten N, Tani C, Tedeschi SK, Touma Z, Schmajuk G, Anic B, Assan F, Chan TM, Clarke AE, Crow MK, Czirják L, Doria A, Graninger W, Halda-Kiss B, Hasni S, Izmirly PM, Jung M, Kumánovics G, Mariette X, Padjen I, Pego-Reigosa JM, Romero-Diaz J, Rúa-Figueroa Fernández Í, Seror R, Stummvoll GH, Tanaka Y, Tektonidou MG, Vasconcelos C, Vital EM, Wallace DJ, Yavuz S, Meroni PL, Fritzler MJ, Naden R, Dörner T, Johnson SR.

Arthritis Rheumatol. 2019 Sep;71(9):1400-1412. doi: 10.1002/art.40930. Epub 2019 Aug 6.

PMID:
31385462
9.

2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus.

Aringer M, Costenbader K, Daikh D, Brinks R, Mosca M, Ramsey-Goldman R, Smolen JS, Wofsy D, Boumpas DT, Kamen DL, Jayne D, Cervera R, Costedoat-Chalumeau N, Diamond B, Gladman DD, Hahn B, Hiepe F, Jacobsen S, Khanna D, Lerstrøm K, Massarotti E, McCune J, Ruiz-Irastorza G, Sanchez-Guerrero J, Schneider M, Urowitz M, Bertsias G, Hoyer BF, Leuchten N, Tani C, Tedeschi SK, Touma Z, Schmajuk G, Anic B, Assan F, Chan TM, Clarke AE, Crow MK, Czirják L, Doria A, Graninger W, Halda-Kiss B, Hasni S, Izmirly PM, Jung M, Kumánovics G, Mariette X, Padjen I, Pego-Reigosa JM, Romero-Diaz J, Rúa-Figueroa Fernández Í, Seror R, Stummvoll GH, Tanaka Y, Tektonidou MG, Vasconcelos C, Vital EM, Wallace DJ, Yavuz S, Meroni PL, Fritzler MJ, Naden R, Dörner T, Johnson SR.

Ann Rheum Dis. 2019 Sep;78(9):1151-1159. doi: 10.1136/annrheumdis-2018-214819. Epub 2019 Aug 5. Review.

10.

[Systemic autoimmune diseases-fit for 2020!]

Aringer M.

Z Rheumatol. 2019 Aug;78(6):499. doi: 10.1007/s00393-019-0682-z. German. No abstract available.

PMID:
31375959
11.

New insights into the prevalence of depressive symptoms and depression in rheumatoid arthritis - Implications from the prospective multicenter VADERA II study.

Englbrecht M, Alten R, Aringer M, Baerwald CG, Burkhardt H, Eby N, Flacke JP, Fliedner G, Henkemeier U, Hofmann MW, Kleinert S, Kneitz C, Krüger K, Pohl C, Schett G, Schmalzing M, Tausche AK, Tony HP, Wendler J.

PLoS One. 2019 May 28;14(5):e0217412. doi: 10.1371/journal.pone.0217412. eCollection 2019.

12.

[Survey of rheumatologists in Saxony, Saxony-Anhalt and Thuringia regarding the occupational situation and activities in further education: no way out of the undersupply of rheumatological care].

Keyßer G, Baerwald CGO, Sieburg M, Boche K, Pfeil A, Kupka TA, Lüthke K, Heldmann F, Oelzner P, Unger L, Aringer M.

Z Rheumatol. 2019 Jun;78(5):479-485. doi: 10.1007/s00393-019-0647-2. German.

PMID:
31087134
13.

2019 update of the EULAR recommendations for the management of systemic lupus erythematosus.

Fanouriakis A, Kostopoulou M, Alunno A, Aringer M, Bajema I, Boletis JN, Cervera R, Doria A, Gordon C, Govoni M, Houssiau F, Jayne D, Kouloumas M, Kuhn A, Larsen JL, Lerstrøm K, Moroni G, Mosca M, Schneider M, Smolen JS, Svenungsson E, Tesar V, Tincani A, Troldborg A, van Vollenhoven R, Wenzel J, Bertsias G, Boumpas DT.

Ann Rheum Dis. 2019 Jun;78(6):736-745. doi: 10.1136/annrheumdis-2019-215089. Epub 2019 Mar 29.

PMID:
30926722
14.

Glucocorticoid Dosages and Acute-Phase Reactant Levels at Giant Cell Arteritis Flare in a Randomized Trial of Tocilizumab.

Stone JH, Tuckwell K, Dimonaco S, Klearman M, Aringer M, Blockmans D, Brouwer E, Cid MC, Dasgupta B, Rech J, Salvarani C, Schulze-Koops H, Schett G, Spiera R, Unizony SH, Collinson N.

Arthritis Rheumatol. 2019 Aug;71(8):1329-1338. doi: 10.1002/art.40876. Epub 2019 Jul 3.

15.

Multicriteria decision analysis process to develop new classification criteria for systemic lupus erythematosus.

Tedeschi SK, Johnson SR, Boumpas DT, Daikh D, Dörner T, Diamond B, Jacobsen S, Jayne D, Kamen DL, McCune WJ, Mosca M, Ramsey-Goldman R, Ruiz-Irastorza G, Schneider M, Urowitz M, Wofsy D, Smolen JS, Naden RP, Aringer M, Costenbader KH.

Ann Rheum Dis. 2019 May;78(5):634-640. doi: 10.1136/annrheumdis-2018-214685. Epub 2019 Jan 28.

16.

Use of Consensus Methodology to Determine Candidate Items for Systemic Lupus Erythematosus Classification Criteria.

Johnson SR, Khanna D, Daikh D, Cervera R, Costedoat-Chalumeau N, Gladman DD, Hahn BH, Hiepe F, Sánchez-Guerrero J, Massarotti E, Boumpas DT, Costenbader KH, Jayne D, Dörner T, Kamen DL, Mosca M, Ramsey-Goldman R, Smolen JS, Wofsy D, Aringer M.

J Rheumatol. 2019 Jul;46(7):721-726. doi: 10.3899/jrheum.180478. Epub 2018 Dec 15.

PMID:
30554156
17.

Association of Dendritic Cell Signatures With Autoimmune Inflammation Revealed by Single-Cell Profiling.

Ashton MP, Eugster A, Dietz S, Loebel D, Lindner A, Kuehn D, Taranko AE, Heschel B, Gavrisan A, Ziegler AG, Aringer M, Bonifacio E.

Arthritis Rheumatol. 2019 May;71(5):817-828. doi: 10.1002/art.40793. Epub 2019 Apr 6.

PMID:
30511817
18.

Swimming against the stream: the fishbowl discussion method as an interactive tool for medical conferences: experiences from the 11th European Lupus Meeting.

Mucke J, Anders HJ, Aringer M, Chehab G, Fischer-Betz R, Hiepe F, Lorenz HM, Schwarting A, Specker C, Voll RE, Schneider M.

Ann Rheum Dis. 2019 May;78(5):713-714. doi: 10.1136/annrheumdis-2018-214160. Epub 2018 Nov 2. No abstract available.

PMID:
30389688
19.

[Immunology of systemic inflammatory diseases].

Aringer M, Schulze-Koops H.

Orthopade. 2018 Nov;47(11):891-898. doi: 10.1007/s00132-018-3647-z. Review. German.

PMID:
30267123
20.

[The S2k guideline: Indications for knee endoprosthesis : Evidence and consent-based indications for total knee arthroplasty].

Lützner J, Lange T, Schmitt J, Kopkow C, Aringer M; DGRh, Böhle E; ZVK, Bork H; DGOU, Dreinhöfer K; DNVF, Friederich N; Deutsche Arthrose-Hilfe e. V, Gravius S; DGOOC, Heller KD; BVOU, Hube R; DKG, Gromnica-Ihle E; Deutsche Rheuma-Liga Bundesverband e. V, Kirschner S; AE, Kladny B; DGOU, Kremer M; DGU, Linke M; Deutsche Gesellschaft für Medizinische Psychologie, Malzahn J; AOK Bundesverband, Sabatowski R; Deutsche Schmerzgesellschaft e. V, Scharf HP, Stöve J, Wagner R; DGORh, Günther KP.

Orthopade. 2018 Sep;47(9):777-781. doi: 10.1007/s00132-018-3612-x. Review. German.

PMID:
30097685
21.

Induction of sustained remission in early inflammatory arthritis with the combination of infliximab plus methotrexate: the DINORA trial.

Stamm TA, Machold KP, Aletaha D, Alasti F, Lipsky P, Pisetsky D, Landewe R, van der Heijde D, Sepriano A, Aringer M, Boumpas D, Burmester G, Cutolo M, Ebner W, Graninger W, Huizinga T, Schett G, Schulze-Koops H, Tak PP, Martin-Mola E, Breedveld F, Smolen J.

Arthritis Res Ther. 2018 Aug 9;20(1):174. doi: 10.1186/s13075-018-1667-z.

22.

Time of Disease-Modifying Antirheumatic Drug Start in Juvenile Idiopathic Arthritis and the Likelihood of a Drug-Free Remission in Young Adulthood.

Minden K, Horneff G, Niewerth M, Seipelt E, Aringer M, Aries P, Foeldvari I, Haas JP, Klein A, Tatsis S, Tenbrock K, Zink A, Klotsche J.

Arthritis Care Res (Hoboken). 2019 Apr;71(4):471-481. doi: 10.1002/acr.23709.

PMID:
30044538
23.

Brief Report: How Do Patients With Newly Diagnosed Systemic Lupus Erythematosus Present? A Multicenter Cohort of Early Systemic Lupus Erythematosus to Inform the Development of New Classification Criteria.

Mosca M, Costenbader KH, Johnson SR, Lorenzoni V, Sebastiani GD, Hoyer BF, Navarra S, Bonfa E, Ramsey-Goldman R, Medina-Rosas J, Piga M, Tani C, Tedeschi SK, Dörner T, Aringer M, Touma Z.

Arthritis Rheumatol. 2019 Jan;71(1):91-98. doi: 10.1002/art.40674. Epub 2018 Nov 26.

PMID:
30035365
24.

How Should We Consider Lupus Without Antinuclear Antibodies?

Daikh DI, Aringer M.

Arthritis Care Res (Hoboken). 2019 Jul;71(7):853-854. doi: 10.1002/acr.23714. No abstract available.

PMID:
30035362
25.

[Systemic Lupus Erythematosus (SLE) - New Classification Criteria].

Aringer M, Dörner T.

Dtsch Med Wochenschr. 2018 Jun;143(11):811-814. doi: 10.1055/a-0542-3409. Epub 2018 May 28. German.

PMID:
29807382
26.

Early symptoms of systemic lupus erythematosus (SLE) recalled by 339 SLE patients.

Leuchten N, Milke B, Winkler-Rohlfing B, Daikh D, Dörner T, Johnson SR, Aringer M; ; on behalf of the SLE Classification Criteria Steering Committee.

Lupus. 2018 Aug;27(9):1431-1436. doi: 10.1177/0961203318776093. Epub 2018 May 17.

PMID:
29771193
27.

Reply.

Leuchten N, Bertsias G, Smolen J, Dörner T, Johnson SR, Aringer M; SLE Classification Criteria Steering Committee.

Arthritis Care Res (Hoboken). 2019 May;71(5):696-697. doi: 10.1002/acr.23558. Epub 2019 Apr 10. No abstract available.

PMID:
29579364
28.

Tocilizumab in the treatment of giant cell arteritis.

Leuchten N, Aringer M.

Immunotherapy. 2018 Mar 1;10(6):465-472. doi: 10.2217/imt-2017-0182. Epub 2018 Mar 5. Review.

PMID:
29504436
29.

[Myelodysplastic syndrome, acute leukemia and stem cell transplantation].

Schmalzing M, Aringer M, Bornhäuser M, Atta J.

Z Rheumatol. 2017 Oct;76(Suppl 2):26-32. doi: 10.1007/s00393-017-0369-2. Review. German.

PMID:
29330757
30.

Multicenter Delphi Exercise to Identify Important Key Items for Classifying Systemic Lupus Erythematosus.

Schmajuk G, Hoyer BF, Aringer M, Johnson SR, Daikh DI, Dörner T; SLE classification criteria steering committee and the international SLE expert panel of the initiative.

Arthritis Care Res (Hoboken). 2018 Oct;70(10):1488-1494. doi: 10.1002/acr.23503. Epub 2018 Sep 11.

31.

Immunoadsorption Followed by Rituximab as a Definitive Treatment for Insulin Autoimmune Syndrome (Hirata Syndrome): A Case Report.

Kroemer TM, Erler A, Tsourdi E, Gruber M, Tselmin S, Julius U, Aringer M, Hofbauer LC, Rachner TD.

Diabetes Care. 2018 Mar;41(3):e23-e24. doi: 10.2337/dc17-1974. Epub 2017 Dec 27. No abstract available.

PMID:
29282202
32.

Long-term glucocorticoid treatment in patients with polymyalgia rheumatica, giant cell arteritis, or both diseases: results from a national rheumatology database.

Albrecht K, Huscher D, Buttgereit F, Aringer M, Hoese G, Ochs W, Thiele K, Zink A.

Rheumatol Int. 2018 Apr;38(4):569-577. doi: 10.1007/s00296-017-3874-3. Epub 2017 Nov 9.

PMID:
29124397
33.

Serum of patients with antiphospholipid syndrome induces adhesion molecules in endothelial cells.

Engel B, Müller G, Roch B, Schröder HE, Aringer M, Bornstein SR, Morawietz H.

Atheroscler Suppl. 2017 Nov;30:141-148. doi: 10.1016/j.atherosclerosissup.2017.05.039. Epub 2017 Jun 2.

PMID:
29096830
34.

Indication Criteria for Total Knee Arthroplasty in Patients with Osteoarthritis - A Multi-perspective Consensus Study.

Schmitt J, Lange T, Günther KP, Kopkow C, Rataj E, Apfelbacher C, Aringer M, Böhle E, Bork H, Dreinhöfer K, Friederich N, Frosch KH, Gravius S, Gromnica-Ihle E, Heller KD, Kirschner S, Kladny B, Kohlhof H, Kremer M, Leuchten N, Lippmann M, Malzahn J, Meyer H, Sabatowski R, Scharf HP, Stoeve J, Wagner R, Lützner J.

Z Orthop Unfall. 2017 Oct;155(5):539-548. doi: 10.1055/s-0043-115120. Epub 2017 Oct 19.

PMID:
29050054
35.

Immunoadsorption in Autoimmune Diseases Affecting the Kidney.

Stummvoll G, Aringer M, Handisurya A, Derfler K.

Semin Nephrol. 2017 Sep;37(5):478-487. doi: 10.1016/j.semnephrol.2017.05.020. Review.

PMID:
28863794
36.

[Still's disease in children and adults].

Hedrich CM, Günther C, Aringer M.

Z Rheumatol. 2017 Sep;76(7):595-608. doi: 10.1007/s00393-017-0358-5. Review. German.

PMID:
28755070
37.

Trial of Tocilizumab in Giant-Cell Arteritis.

Stone JH, Tuckwell K, Dimonaco S, Klearman M, Aringer M, Blockmans D, Brouwer E, Cid MC, Dasgupta B, Rech J, Salvarani C, Schett G, Schulze-Koops H, Spiera R, Unizony SH, Collinson N.

N Engl J Med. 2017 Jul 27;377(4):317-328. doi: 10.1056/NEJMoa1613849.

38.

Developing and Refining New Candidate Criteria for Systemic Lupus Erythematosus Classification: An International Collaboration.

Tedeschi SK, Johnson SR, Boumpas D, Daikh D, Dörner T, Jayne D, Kamen D, Lerstrøm K, Mosca M, Ramsey-Goldman R, Sinnette C, Wofsy D, Smolen JS, Naden RP, Aringer M, Costenbader KH.

Arthritis Care Res (Hoboken). 2018 Apr;70(4):571-581. doi: 10.1002/acr.23317. Epub 2018 Feb 22. Review.

39.

Janus kinase inhibitors clear to land: Janus kinase inhibitors in RA.

Aringer M.

Rheumatology (Oxford). 2017 Jun 13. doi: 10.1093/rheumatology/kex217. [Epub ahead of print] No abstract available.

PMID:
28633283
40.

[Safety and efficacy of off-label use of biologic therapies in patients with inflammatory rheumatic diseases refractory to standard of care therapy : Data from a nationwide German registry (GRAID2)].

Proft F, Schulze-Koops H, Grunke M, Schrezenmeier E, Halleck F, Henes J, Unger L, Schmidt E, Fiehn C, Jacobi A, Iking-Konert C, Kneitz C, Schmidt RE, Bannert B, Voll RE, Fischer-Betz R, Kötter I, Tony HP, Holle J, Aringer M, Erler A, Behrens F, Burmester GR, Dörner T.

Z Rheumatol. 2018 Feb;77(1):28-39. doi: 10.1007/s00393-017-0330-4. German.

PMID:
28589389
41.

Performance of Antinuclear Antibodies for Classifying Systemic Lupus Erythematosus: A Systematic Literature Review and Meta-Regression of Diagnostic Data.

Leuchten N, Hoyer A, Brinks R, Schoels M, Schneider M, Smolen J, Johnson SR, Daikh D, Dörner T, Aringer M, Bertsias G; Systemic Lupus Erythematosus Classification Criteria Steering Committee.

Arthritis Care Res (Hoboken). 2018 Mar;70(3):428-438. doi: 10.1002/acr.23292. Epub 2018 Jan 30.

42.

[Still's disease in children and adults].

Hedrich CM, Günther C, Aringer M.

Hautarzt. 2017 Jun;68(6):497-511. doi: 10.1007/s00105-017-3983-7. Review. German.

PMID:
28451698
43.

A chronic recurrent disease course of dermatomyositis is associated with autoantibodies against transcriptional intermediary factor 1-γ.

Meisterfeld S, Röber N, Conrad K, Beissert S, Aringer M, Günther C.

Br J Dermatol. 2017 Aug;177(2):590-593. doi: 10.1111/bjd.15468. Epub 2017 Jul 5. No abstract available.

PMID:
28314058
44.

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update.

Smolen JS, Landewé R, Bijlsma J, Burmester G, Chatzidionysiou K, Dougados M, Nam J, Ramiro S, Voshaar M, van Vollenhoven R, Aletaha D, Aringer M, Boers M, Buckley CD, Buttgereit F, Bykerk V, Cardiel M, Combe B, Cutolo M, van Eijk-Hustings Y, Emery P, Finckh A, Gabay C, Gomez-Reino J, Gossec L, Gottenberg JE, Hazes JMW, Huizinga T, Jani M, Karateev D, Kouloumas M, Kvien T, Li Z, Mariette X, McInnes I, Mysler E, Nash P, Pavelka K, Poór G, Richez C, van Riel P, Rubbert-Roth A, Saag K, da Silva J, Stamm T, Takeuchi T, Westhovens R, de Wit M, van der Heijde D.

Ann Rheum Dis. 2017 Jun;76(6):960-977. doi: 10.1136/annrheumdis-2016-210715. Epub 2017 Mar 6. Review.

45.

The Role of the Neutrophil to Lymphocyte Ratio for Survival Outcomes in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Abiraterone.

Boegemann M, Schlack K, Thomes S, Steinestel J, Rahbar K, Semjonow A, Schrader AJ, Aringer M, Krabbe LM.

Int J Mol Sci. 2017 Feb 11;18(2). pii: E380. doi: 10.3390/ijms18020380.

46.

Recent advances in managing systemic sclerosis.

Aringer M, Erler A.

F1000Res. 2017 Jan 30;6:88. doi: 10.12688/f1000research.10022.1. eCollection 2017. Review.

47.

[Tapering and termination of immunosuppressive therapy : Systemic lupus erythematosus].

Aringer M, Leuchten N, Fischer-Betz R.

Z Rheumatol. 2017 Feb;76(1):27-32. doi: 10.1007/s00393-016-0258-0. Review. German.

PMID:
28097391
48.

[Lupus erythematosus - Update 2016].

Aringer M, Voll RE.

Dtsch Med Wochenschr. 2016 Nov;141(24):1785-1788. Epub 2016 Nov 30. Review. German.

PMID:
27903029
49.

A framework for remission in SLE: consensus findings from a large international task force on definitions of remission in SLE (DORIS).

van Vollenhoven R, Voskuyl A, Bertsias G, Aranow C, Aringer M, Arnaud L, Askanase A, Balážová P, Bonfa E, Bootsma H, Boumpas D, Bruce I, Cervera R, Clarke A, Coney C, Costedoat-Chalumeau N, Czirják L, Derksen R, Doria A, Dörner T, Fischer-Betz R, Fritsch-Stork R, Gordon C, Graninger W, Györi N, Houssiau F, Isenberg D, Jacobsen S, Jayne D, Kuhn A, Le Guern V, Lerstrøm K, Levy R, Machado-Ribeiro F, Mariette X, Missaykeh J, Morand E, Mosca M, Inanc M, Navarra S, Neumann I, Olesinska M, Petri M, Rahman A, Rekvig OP, Rovensky J, Shoenfeld Y, Smolen J, Tincani A, Urowitz M, van Leeuw B, Vasconcelos C, Voss A, Werth VP, Zakharova H, Zoma A, Schneider M, Ward M.

Ann Rheum Dis. 2017 Mar;76(3):554-561. doi: 10.1136/annrheumdis-2016-209519. Epub 2016 Nov 24. Review.

50.

[Management of systemic lupus erythematosus].

Aringer M, Schneider M.

Internist (Berl). 2016 Nov;57(11):1052-1059. Review. German.

PMID:
27670650

Supplemental Content

Loading ...
Support Center